Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old

Launched by UPSHER-SMITH LABORATORIES · Feb 5, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Qudexy XR to see if it can help prevent migraines in children aged 6 to 11 years. Migraines can be very disruptive, and this study aims to find out if this treatment could make a difference for kids who suffer from frequent headaches. To be eligible for the study, children must have a history of migraines, with at least eight headache days in the month before the trial starts, and they need to weigh between 17 to 50 kilograms.

Participants in the trial will be closely monitored to see how well Qudexy XR works for them. The study is currently looking for volunteers, and it’s important to note that there are certain criteria that would exclude a child from participating, such as having continuous migraines or being on certain other medications. This trial represents a chance for affected children to potentially find relief from their migraines and improve their daily activities.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subject is a female or male 6 to 11 years of age, inclusive, at Visit 1 (Screening)
• • 2. Subject weighs at least 17.0 kg and less than 50.0 kg at Visit 1 (Screening) based on 95 percentile weight for the age range.11
• • 3. Subject has at least a 6-month history of headaches consistent with a diagnosis of migraine with or without aura (International Classification of Headache Disorders, 3rd Edition \[ICHD 3\]).
• • 4. Subject had ≥8 self-reported headache days in the 28 days prior to Screening.
• • 5. Subject has a PedMIDAS score \>10, indicating at least mild disruption in daily activities, and \<140, indicating extreme disability that may require more comprehensive, multi component therapy.
• Exclusion Criteria:
• • 1. Subject has continuous migraines, defined as an unrelenting headache for a 28-day period.
• • 2. Subject is currently receiving treatment or has used Botulinum toxin (Botox®) within 3 months prior to Visit 1 (Screening).
• • 3. Subject is currently receiving migraine prevention medication and has initiated or changed the dose within 28 days of Screening or is unwilling to avoid making a change during the duration of the study.
• • 4. Subject has previously failed an adequate trial of topiramate (at least 3 months duration at a clinically appropriate dose) for prophylaxis of migraine headache due to lack of efficacy or AEs.
• • 5. Subject has previously failed an adequate trial of \>3 migraine preventative medications.
• • 6. Subject has a known history of allergic reaction to topiramate or any excipient in Qudexy XR.
• • 7. Subject has a diagnosis or history of disease that may interfere with safety or evaluation of the study drug.
• • 8. Subject is currently using an investigational drug or device or has used such within 30 days prior to Visit 1.
• 9. Subject has begun menses and any of the following:
• • 1. Subject has tested positive for pregnancy; OR
• • 2. Subject is pregnant, planning pregnancy, or lactating; OR
• • 3. Subject is taking an oral hormonal contraceptive (either combined \[estrogen and progestogen containing\] or progestogen-only) and is unable or unwilling to switch to an alternative highly effective contraceptive method.